MedPath

Calcitriol

Generic Name
Calcitriol
Brand Names
Rocaltrol, Vectical
Drug Type
Small Molecule
Chemical Formula
C27H44O3
CAS Number
32222-06-3
Unique Ingredient Identifier
FXC9231JVH
Background

Calcitriol is an active metabolite of vitamin D with 3 hydroxyl (OH) groups and is commonly referred to as 1,25-dihydroxycholecalciferol, or 1alpha,25-dihydroxyvitamin D, 1,25-dihydroxyvitamin D. It is produced in the body after series of conversion steps of 7-dehydrocholesterol from exposure to UV light. 7-dehydrocholesterol is converted to Vitamin D3 (vitamin D3) in the skin, which is then converted to Calcifediol in the liver and kidneys. Calcifediol undergoes hydroxylation to form calcitriol via 1α-hydroxylase (CYP27B1) activity . Calcitriol is considered to be the most potent metabolite of vitamin D in humans . Renal production of calcitriol is stimulated in response to PTH, low calcium and low phosphate . Calcitriol plays a role in plasma calcium regulation in concert with parathyroid hormone (PTH) by enhancing absorption of dietary calcium and phosphate from the gastrointestinal tract, promoting renal tubular reabsorption of calcium in the kidneys, and stimulating the release of calcium stores from the skeletal system. In addition to promoting fatty acid synthesis and inhibiting lipolysis, calcitriol has been demonstrated to increase energy efficiency by suppressing UCP2 expression, which is modulated by signaling pathways of classical nuclear receptors (nVDR), where calcitriol acts as a natural ligand . There is also evidence that calcitriol modulates the action of cytokines and may regulate immune and inflammatory response, cell turnover, cell differentiation .

Administered orally and intravenously, calcitriol is commonly used as a medication in the treatment of secondary hyperparathyroidism and resultant metabolic bone disease, hypocalcemia in patients undergoing chronic renal dialysis, and osteoporosis. It is also available in topical form for the treatment of mild to moderate plaque psoriasis in adults. Calcitriol is marketed under various trade names including Rocaltrol (Roche), Calcijex (Abbott) and Decostriol (Mibe, Jesalis).

Indication

Used to treat vitamin D deficiency or insufficiency, refractory rickets (vitamin D resistant rickets), familial hypophosphatemia and hypoparathyroidism, and in the management of hypocalcemia and renal osteodystrophy in patients with chronic renal failure undergoing dialysis. Also used in conjunction with calcium in the management and prevention of primary or corticosteroid-induced osteoporosis.

Associated Conditions
Hypocalcemia, Mild to Moderate Plaque Psoriasis, Osteodystrophy, Secondary Hyperparathyroidism (SHPT), Vitamin D Resistant Rickets

Effects of Vitamin D on Renin Expression in Hypertensive Patients

Early Phase 1
Terminated
Conditions
Hypertension
Vitamin D Deficiency
Interventions
Drug: Placebo
First Posted Date
2008-01-03
Last Posted Date
2016-05-27
Lead Sponsor
University of Utah
Target Recruit Count
12
Registration Number
NCT00585442
Locations
🇺🇸

University of Utah, Salt Lake City, Utah, United States

A Study of Gemcitabine ± Erlotinib and DN-101 Versus Gemcitabine ± Erlotinib and Placebo in Patients With Advanced Pancreatic Cancer

First Posted Date
2007-09-28
Last Posted Date
2007-11-06
Lead Sponsor
Novacea
Target Recruit Count
132
Registration Number
NCT00536770
Locations
🇺🇸

Novacea Investigational Site, Nashville, Tennessee, United States

The Efficacy and Safety of Calcitriol for the Treatment of Lupus Nephritis and Persistent Proteinuria

Phase 4
Withdrawn
Conditions
Systemic Lupus Erythematosus
Nephritis
Proteinuria
Interventions
Drug: Multivitamin
First Posted Date
2007-07-30
Last Posted Date
2015-08-04
Lead Sponsor
Chinese University of Hong Kong
Registration Number
NCT00508898

Vitamin D and Blood Pressure

Not Applicable
Withdrawn
Conditions
Hypertension
Interventions
First Posted Date
2007-04-12
Last Posted Date
2014-01-08
Lead Sponsor
Atlanta VA Medical Center
Registration Number
NCT00459563
Locations
🇺🇸

VAMC, Decatur, Georgia, United States

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

Not Applicable
Completed
Conditions
Rheumatoid Arthritis
Crohn's Disease
Interventions
First Posted Date
2007-01-29
Last Posted Date
2013-02-04
Lead Sponsor
Atlanta VA Medical Center
Target Recruit Count
9
Registration Number
NCT00427804
Locations
🇺🇸

Atlanta VAMC, Atlanta, Georgia, United States

A Study of Calcitriol BID Topical Treatment in Adolescents With Plaque Psoriasis

Phase 2
Completed
Conditions
Chronic Plaque Psoriasis
Interventions
First Posted Date
2007-01-09
Last Posted Date
2021-02-18
Lead Sponsor
Galderma R&D
Target Recruit Count
25
Registration Number
NCT00419666
Locations
🇺🇸

Children's Hospital, Department of Pediatric and Adolescent Dermatology, San Diego, California, United States

🇺🇸

Center for Clinical Studies, Webster, Texas, United States

🇺🇸

Dermatology Center For Children & Young Adults, Eagan, Minnesota, United States

and more 4 locations

A Phase II Trial of Calcitriol and Naproxen in Patients With Recurrent Prostate Cancer

Phase 2
Terminated
Conditions
Prostatic Neoplasms
Prostate Cancer
First Posted Date
2006-10-03
Last Posted Date
2013-01-28
Lead Sponsor
Stanford University
Target Recruit Count
20
Registration Number
NCT00383487
Locations
🇺🇸

Stanford University School of Medicine, Stanford, California, United States

Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy

Phase 4
Completed
Conditions
IGA Nephropathy
First Posted Date
2006-04-27
Last Posted Date
2009-01-30
Lead Sponsor
Chinese University of Hong Kong
Target Recruit Count
10
Registration Number
NCT00319761
Locations
🇭🇰

Department of Medicine & Therapeutics, Prince of Wales Hospital, Hong Kong, Hong Kong

Effect of Vitamin D and Calcium on Genes in the Colon

Phase 1
Completed
Conditions
Colorectal Polyps
Colorectal Adenoma
Adenocarcinoma
Interventions
First Posted Date
2006-03-02
Last Posted Date
2011-11-18
Lead Sponsor
Rockefeller University
Target Recruit Count
10
Registration Number
NCT00298545
Locations
🇺🇸

Rockefeller University Hospital, New York, New York, United States

DN-101 in Combination With Docetaxel in Androgen-Independent Prostate Cancer (AIPC) (AIPC Study of Calcitriol Enhancing Taxotere [ASCENT-2])

Phase 3
Terminated
Conditions
Prostate Cancer
First Posted Date
2006-01-09
Last Posted Date
2007-11-06
Lead Sponsor
Novacea
Target Recruit Count
1200
Registration Number
NCT00273338
Locations
🇺🇸

UCLA department of Urology, Los Angeles, California, United States

🇺🇸

Hematology Oncology Associates of Illinois, Chicago, Illinois, United States

🇺🇸

The Cleveland Clinic Foundation, Cleveland, Ohio, United States

and more 209 locations
© Copyright 2025. All Rights Reserved by MedPath